Trial Profile

Efficacy and safety study of MH-004 in mild to moderate atopic dermatitis patients

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 02 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tofacitinib etocomil (Primary)
Indications Atopic dermatitis
Focus Therapeutic Use
Sponsors Minghui Pharmaceutical (Shanghai)

Most Recent Events

02 Dec 2024 Planned number of patients changed to 377.
17 Aug 2023 According to a Minghui Pharmaceutical Inc. media release, company anticipates sharing the topline data of the phase 3 trial with the medical community and regulatory authorities in H2 2024.
17 Aug 2023 Status changed to recruiting, according to a Minghui Pharmaceutical Inc. media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com